ASX Announcement – Successful Clinical Study Results
“THOROUGH QT/QTc” PENTHROX® CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES
Medical Developments International Limited (ASX:MVP) is delighted to announce it has completed the
Thorough QT/QTc Clinical Trial.
- Primary Objective met
- All Secondary Objectives were met
- Safety conclusions:
a. There were no safety concerns associated with the administration of a supratherapeutic single dose of methoxyflurane;
b. There was no evidence of any effect of methoxyflurane on the heart rate, on the RR interval, PR interval or QRS duration, or on ECG morphology;
c. There were no safety concerns assessed by clinical laboratory tests, including kidney and liver function tests, and vital signs.
- Methoxyflurane (Penthrox™) did not have a QT prolongation of regulatory concern
- The QT/QTc Clinical Trial was completed on time and on budget.
Download MVP ASX Announcement – Successful Clinical Study Results PDF